Evidence map›Paper›PMID 28698456›Full record

ArticleMolecules (Basel, Switzerland)2017

Combining NMR Spectroscopy and Chemometrics to Monitor Structural Features of Crude Hep-arin.

Lucio Mauri, Maria Marinozzi, Giulia Mazzini, Richard E Kolinski, Michael Karfunkle, David A Keire, Marco Guerrini

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Quality Control of Heparin Injections: Comparison of Four Established Methods.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2020
    Article
  4. Review
  5. Review
  6. Article
  7. Heparan Sulfate Proteoglycans as Relays of Neuroinflammation.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lucio MauriInstitute for Chemical and Biochemical Research G. Ronzoni, via G. Colombo 81, 20133 Milan, Italy. mauri@ronzoni.it.
Maria MarinozziInstitute for Chemical and Biochemical Research G. Ronzoni, via G. Colombo 81, 20133 Milan, Italy. maria.marinozzi90@gmail.com.
Giulia MazziniInstitute for Chemical and Biochemical Research G. Ronzoni, via G. Colombo 81, 20133 Milan, Italy. giulia.mazzini@gmail.com.
Richard E KolinskiDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 645 S. Newstead Ave., St. Louis, MO 63110, USA. Richard.kolinski@fda.hhs.gov.
Michael KarfunkleDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 645 S. Newstead Ave., St. Louis, MO 63110, USA. michael.karfunkle@fda.hhs.gov.
David A KeireDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 645 S. Newstead Ave., St. Louis, MO 63110, USA. David.Keire@fda.hhs.gov.
Marco GuerriniInstitute for Chemical and Biochemical Research G. Ronzoni, via G. Colombo 81, 20133 Milan, Italy. guerrini@ronzoni.it.
Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni · ITUnited States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of the complexity and global nature of the heparin supply chain, the control of heparin quality during manufacturing steps is essential to ensure the safety of the final active pharmaceutical ingredient (API). For this reason, there is a need to develop consistent analytical methods able to assess the quality of heparin early in production (i.e., as the crude heparin before it is purified to API under cGMP conditions). Although a number of analytical techniques have been applied to characterize heparin APIs, few of them have been applied for crude heparin structure and composition analyses. Here, to address this issue, NMR spectroscopy and chemometrics were applied to characterize 88 crude heparin samples. The samples were also analyzed by strong anion exchange HPLC (SAX-HPLC) as an orthogonal check of the purity levels of the crudes analyzed by NMR. The HPLC data showed that the chemometric analysis of the NMR data differentiated the samples based on their purity. These orthogonal approaches differentiated samples according their glycosaminoglycan (GAG) composition and their mono and disaccharide composition and structure for each GAG family (e.g., heparin/heparan, dermatan sulfate, and chondroitin sulfate A). Moreover, quantitative HSQC and multivariate analysis (PCA) were used to distinguish between crude heparin of different animal and tissue sources.

Indexed as

AnimalsChromatography, High Pressure LiquidDermatan SulfateDrug ContaminationGlycosaminoglycansHeparinHumansMagnetic Resonance SpectroscopyQuality ControlDermatan SulfateGlycosaminoglycansHeparinchemometriccrude heparinheparinHSQCNMRPCAquantitative NMR

Identifiers

PMID28698456
PMCPMC6152302
OpenAlexW2724610542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.